The FDA has given the go.ahead to the monoclonals for the under 12s

The US FDA has expanded the emergency use authorization for bamlanivimab and etesevimab antibodies administered together for patients under 12 years of age. This was reported by the manufacturer, Eli Lilly, noting that it is the first authorized antibody treatment for children and infants at high risk of becoming seriously ill.

By Editor

Leave a Reply